DXR Inhibition by Potent Mono- and Disubstituted Fosmidomycin Analogues

Citations Over TimeTop 12% of 2013 papers

Abstract

The antimalarial compound fosmidomycin targets DXR, the enzyme that catalyzes the first committed step in the MEP pathway, producing the essential isoprenoid precursors, isopentenyl diphosphate and dimethylallyl diphosphate. The MEP pathway is used by a number of pathogens, including Mycobacterium tuberculosis and apicomplexan parasites, and differs from the classical mevalonate pathway that is essential in humans. Using a structure-based approach, we designed a number of analogues of fosmidomycin, including a series that are substituted in both the Cα and the hydroxamate positions. The latter proved to be a stable framework for the design of inhibitors that extend from the polar and cramped (and so not easily druggable) substrate-binding site and can, for the first time, bridge the substrate and cofactor binding sites. A number of these compounds are more potent than fosmidomycin in terms of killing Plasmodium falciparum in an in vitro assay; the best has an IC50 of 40 nM.

Related Papers

• → Druggability of the enzymes of the non-mevalonate-pathway(2013)61 cited
• → Druggability analysis and classification of protein tyrosine phosphatase active sites(2016)51 cited
• → Evolutionary Survey of Druggable Protein Targets with Respect to Their Subcellular Localizations(2013)22 cited
• → Network motifs modulate druggability of cellular targets(2016)13 cited
• → Druggability Prediction(2012)5 cited